Trioz Biosciences is a pioneering biopharmaceutical company dedicated to developing novel products for cancer care. Recognizing that most cancer patients undergo chemo and radiation therapy, we address the variable long-term effectiveness caused by complex metabolic reprogramming in cancer cells.

​

​Our mission is to revolutionize cancer treatment by applying tailored nutraceutical solutions. Our flagship product, "SYNTROZ™," represents a state-of-the-art advancement meticulously crafted to bolster cancer patients' resilience against the disease.

​

We firmly believe that metabolic science will be a foundational component of future cancer therapies, which have remained essentially unchanged for decades. SYNTROZ™, our evidence-based product, integrates a deep mechanistic understanding of metabolic science and how nutrients influence tumor growth and cancer treatment. We are dedicated to providing an effective, complementary approach to support traditional cancer therapies, improving patient quality of life and treatment efficacy.